11 projets européens trouvés
Recherche sur 125080 projets européens
TERMINÉ
Conservative iron chelation as a disease-modifying strategy in Parkinson’s disease: a multicentric, parallel-group, placebo-controlled, randomized clinical trial of deferiprone (FAIR-PARK-II)
Date du début: 1 mai 2015, Date de fin: 30 avr. 2020,
... moderate-dose DFP (30 mg/kg/day) slows the progression of handicap in de novo PD patients while not affecting systemic parameters. The 9-month, parallel-group, randomized, placebo-controlled, multicentre trial will be followed by a 1-month wash-out period. The primary efficacy criterion will be the change in motor and non-motor handicap scores on the Total Movement Disorders Society Unified Parki ...
Voir le projet
17
Participants partenaires
TERMINÉ
DC-based immunotherapy to treat Malignant Mesothelioma (H2020MM04)
Date du début: 1 janv. 2016, Date de fin: 31 déc. 2019,
Asbestos is one of the major occupational carcinogens. The European Union has an extensive history of protecting workers and consumers against asbestos and even adopted a resolution 2012/2065(INI) ‘on asbestos related occupational health threats and prospects for abolishing all existing asbestos’ last year. Although asbestos is banned, it is still massively present in the built environment. Millio ...
Voir le projet
8
Participants partenaires
TERMINÉ
DIabetes REsearCh on patient sTratification (DIRECT)
Date du début: 1 févr. 2012, Date de fin: 31 janv. 2019,
The overarching aims of the DIRECT consortium, consisting of 20 leading academic groups in diabetes and 5 EFPIA companies, are to identify biomarkers that address current bottlenecks in diabetes drug development and to develop a stratified medicines approach to treatment of type 2 diabetes with either existing or novel therapies.There is heterogeneity in who develops diabetes, the rate at which th ...
Voir le projet
27
Participants partenaires
TERMINÉ
"Therapeutic Beta-Lactam Monitoring for Stratified Treatment of hospital-acquired pneumonia, improved dose-dependent efficacy, decreased treatment duration, and prevention of emergence of resistance" (MON4STRAT)
Date du début: 1 févr. 2014, Date de fin: 31 janv. 2018,
...cable dose adjustments during treatment and thus (iii) to improve efficacy while reducing risk of EDR or adverse effects.The MON4STRAT approach will be validated through a prospective, multicentre, randomized clinical trial with150 adults. Its applicability in paediatrics will be tested through an observational study with 70 children/neonates.Being generic in nature, MON4STRAT will be replicable t ...
Voir le projet
13
Participants partenaires
TERMINÉ
European multicentre, randomised, phase III clinical trial of hypothermia plus best medical treatment versus best medical treatment alone for acute ischaemic stroke (EuroHYP-1)
Date du début: 1 févr. 2012, Date de fin: 31 janv. 2017,
The consortium led by UKER and EuroHYP, the European Stroke Research Network for Hypothermia, proposes a large, multicentre clinical trial which will assess mild hypothermia as a novel treatment for ischemic stroke.Stroke is the second cause of death world-wide and the second cause of lost disability-adjusted life years in high-income countries. Stroke incidence rises exponentially with age, so it ...
Voir le projet
38
Participants partenaires
TERMINÉ
A European multicentre double-blind placebo-controlled phase III trial of nilvadIpine in mild to moderate Alzheimer’s disease (NILVAD)
Date du début: 1 janv. 2012, Date de fin: 31 déc. 2016,
Alzheimer’s disease (AD) is an ever-increasing public health concern among the aging population and is the most common form of dementia affecting more than 15 million individuals worldwide and around 5 million Europeans. The direct and indirect costs of AD and other dementias amount to more than €440,000 million each year (www.alz.org, 2010).Even modest therapeutic advances that delay disease onse ...
Voir le projet
17
Participants partenaires
TERMINÉ
Development of biophotonic device based on flexible light emitting textile dedicated to the monitoring and treatment for dermatologic diseases and carcinoma (PHOS-ISTOS)
Date du début: 1 déc. 2013, Date de fin: 30 nov. 2016,
The therapeutic effect of the photodynamic therapy (PDT) depends on a combination of parameters that include drug dose, drug-light interval, oxygen in cells and light irradiance rate. It also varies according to the wavelength distribution of the light source. Finally, a homogeneous and reproducible illumination during the clinical PDT is determinant in preventing under- or overtreatment. So, the ...
Voir le projet
12
Participants partenaires
TERMINÉ
Persistent virus infection as a cause of pathogenic inflammation in type 1 diabetes - an innovative research program of biobanks and expertise (PEVNET)
Date du début: 1 janv. 2011, Date de fin: 30 juin 2016,
"Type 1 diabetes is caused by an inflammatory process which damage insulin-producing beta-cells in the pancreas. It is one of the most common chronic diseases and its incidence is rapidly increasing. Due to its complications it causes a significant medical and economic burden to European society. A causal association between enterovirus and type 1 diabetes has become more and more likely. The aim ...
Voir le projet
14
Participants partenaires
TERMINÉ
Development of 6-mercaptopurine and Methotrexate oral liquid formulations for the maintenance treatment of Acute Lymphoblastic Leukæmia in children (LOULLA&PHILLA)
Date du début: 1 nov. 2008, Date de fin: 30 avr. 2012,
"Only for Children Pharmaceuticals, a French based Small and Medium-sized Enterprise (SME) developing drug for children, is the Coordinator of a multinational, multidisciplinary and complementary Consortium. This Consortium is composed of highly qualified organizations and notorious clinicians in pediatric hemato-oncology. The Consortium is an integrated team of competencies (clinicians, pædiatric ...
Voir le projet
12
Participants partenaires
TERMINÉ
Mitochondrial dysfunction in neurodegenerative diseases: towards new therapeutics (Mitotarget)
Date du début: 1 févr. 2009, Date de fin: 31 mars 2012,
Mitochondrial dysfunction is a major hallmark of various neurodegenerative disorders including Alzheimer’s disease, Parkinson’s disease, Huntington’s diseases or Amyotrophic Lateral Sclerosis (ALS). However linking mitochondrial dysfunction to the pathogenesis of some of these diseases still needs to be elucidated. Furthermore, in pathologies where this link is already established, the question re ...
Voir le projet
19
Participants partenaires
TERMINÉ
PATIENT SAFETY THROUGH INTELLIGENT PROCEDURES IN MEDICATION (PSIP)
Date du début: 1 janv. 2008, Date de fin: 31 juil. 2011,
Adverse Drug Events (ADE) due to product safety problems, and medication errors due to human factors (HF) are a major Public Health issue. They endanger the patients' safety and originate considerable extra hospital costs.Healthcare ICT applications should help reducing the prevalence of preventable ADE, by providing healthcare professionals and patients with relevant knowledge (guidelines, recomm ...
Voir le projet